Subsequent chemotherapy with paclitaxel plus cetuximab-based chemotherapy following immune checkpoint inhibitor in recurrent or metastatic squamous cell carcinoma of the head and neck

Subsequent chemotherapy with paclitaxel plus cetuximab-based chemotherapy following immune checkpoint inhibitor in recurrent or metastatic squamous cell carcinoma of the head and neck

BackgroundImmune checkpoint inhibitors (ICIs) are essential in treating recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). However, the overall response rate (ORR) is limited to 10-20%, and subsequent chemotherapy is critical to maximizing the subjects’ prognosis.MethodsW...

Full description

Bibliographic Details
Main Authors:	Hideki Tanaka, Tomohiro Enokida, Susumu Okano, Takao Fujisawa, Nobukazu Tanaka, Naohiro Takeshita, Ryutaro Onaga, Yuta Hoshi, Akihisa Wada, Masanobu Sato, Yuri Ueda, Makoto Tahara
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-11-01
Series:	Frontiers in Oncology
Subjects:	pembrolizumab subsequent chemotherapy paclitaxel cetuximab carboplatin recurrent/metastasis squamous cell carcinoma of the head and neck
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1221352/full

Similar Items

Induction chemotherapy with paclitaxel, carboplatin and cetuximab for locoregionally advanced nasopharyngeal carcinoma: A single-center, retrospective study
by: Naohiro Takeshita, et al.
Published: (2022-08-01)

Combination chemotherapy with taxane and platinum in patients with salivary gland carcinoma: a retrospective study of docetaxel plus cisplatin and paclitaxel plus carboplatin
by: Ryutaro Onaga, et al.
Published: (2023-06-01)

Combination Treatment With Paclitaxel, Carboplatin, and Cetuximab (PCE) as First-Line Treatment in Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma
by: Yuri Ueda, et al.
Published: (2020-10-01)

Paclitaxel Plus Cetuximab as 1st Line Chemotherapy in Platinum-Based Chemoradiotherapy-Refractory Patients With Squamous Cell Carcinoma of the Head and Neck
by: Tomohiro Enokida, et al.
Published: (2018-08-01)

A multicenter phase II trial of paclitaxel, carboplatin, and cetuximab followed by chemoradiotherapy in patients with unresectable locally advanced squamous cell carcinoma of the head and neck
by: Tomohiro Enokida, et al.
Published: (2020-03-01)

Concurrent Radiotherapy with Carboplatin and Cetuximab for the Treatment of Medically Compromised Patients with Locoregionally Advanced Head and Neck Squamous Cell Carcinoma
by: Kunal eSaigal, et al.
Published: (2014-06-01)

Weekly Paclitaxel, Carboplatin, and Cetuximab as First-Line Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma for Patients Ineligible to Cisplatin-Based Chemotherapy: A Retrospective Monocentric Study in 60 Patients
by: Hélène Carinato, et al.
Published: (2021-10-01)

High Response Rate to Carboplatin-Paclitaxel-Cetuximab and Pembrolizumab in Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
by: Bruno Chauffert, et al.
Published: (2023-01-01)

Cetuximab-Taxanes-Platinum-Fluorouracil/Capecitabine (C-TPF/C-TPX) – a Feasible Option for Recurrent HNSCC with Negative Prognostic Factors. Literature Review with a Case Presentation
by: Camil Ciprian MIRESTEAN, et al.
Published: (2023-03-01)

Treatment outcomes of standard (high dose) cisplatin and non‐standard chemotherapy for locally advanced head and neck cancer
by: Muhammad Alamgeer, et al.
Published: (2023-01-01)

Randomized Phase II Study with Cetuximab in Combination with 5-FU and Cisplatin or Carboplatin Vs. Cetuximab in Combination with Paclitaxel and Carboplatin for Treatment of Patients with Relapsed or Metastatic Squamous Cell Carcinoma of the Head and Neck (CETMET Trial)
by: Georgios Tsakonas, et al.
Published: (2020-10-01)

Observational, prospective, phase 4 study in patients with first‐line recurrent and/or metastatic squamous cell carcinoma of the head and neck treated with cetuximab and platinum‐based therapy: DIRECT
by: Joël Guigay, et al.
Published: (2022-02-01)

Efficacy of Cetuximab in Combination with Chemotherapy in Advanced Non-small Cell Lung Cancer
by: Sheng YANG, et al.
Published: (2016-05-01)

A Prospective Real-World Multi-Center Study to Evaluate Progression-Free and Overall Survival of Radiotherapy with Cetuximab and Platinum-Based Chemotherapy with Cetuximab in Locally Recurrent Head and Neck Cancer
by: Markus Hecht, et al.
Published: (2021-07-01)

Combination Chemotherapy of Azacitidine and Cetuximab for Therapy-Related Acute Myeloid Leukemia following Oxaliplatin for Metastatic Colorectal Cancer
by: Akari Hashimoto, et al.
Published: (2014-05-01)

Biweekly cetuximab and first-line chemotherapy in chinese patients with k-ras wild-type colorectal cancers
by: Wing-Lok Chan, et al.
Published: (2014-01-01)

Tracheal cancer treated with a short course of external and endoluminal radio-chemotherapy combined with cetuximab – a case report
by: Michael I. Koukourakis, et al.
Published: (2010-01-01)

First‐line therapy of bevacizumab plus chemotherapy versus cetuximab plus chemotherapy for metastatic colorectal cancer patients with mucinous adenocarcinoma or mucinous component
by: Yu‐Wen Zhou, et al.
Published: (2021-05-01)

Incidence and risk factors of hypomagnesemia in head and neck cancer patients treated with cetuximab
by: Tomohiro Enokida, et al.
Published: (2016-09-01)

Histological transformation to signet-ring cell carcinoma in a patient with clinically aggressive poorly differentiated adenocarcinoma of the ascending colon after response to chemotherapy plus cetuximab: a case report
by: Hideki Nagano, et al.
Published: (2023-06-01)

Avelumab in Combination With Cetuximab and Chemotherapy as First-Line Treatment for Patients With Advanced Squamous NSCLC
by: Zoran Andric, MD, et al.
Published: (2023-02-01)

Long-Term Survival of Patients With Chemotherapy-Naïve Metastatic Nasopharyngeal Carcinoma Receiving Cetuximab Plus Docetaxel and Cisplatin Regimen
by: Mengping Zhang, et al.
Published: (2020-06-01)

Successful rechallenge with cetuximab after progression with nivolumab for recurrent cervical lymph node metastasis from carcinoma of the tongue
by: Yasuyuki Asada, et al.
Published: (2021-07-01)

A Multicenter Phase II Trial of Docetaxel, Cisplatin, and Cetuximab (TPEx) Followed by Cetuximab and Concurrent Radiotherapy for Patients With Local Advanced Squamous Cell Carcinoma of the Head and Neck (CSPOR HN01: ECRIPS Study)
by: Sadamoto Zenda, et al.
Published: (2019-01-01)

Paclitaxel Plus Cetuximab as Induction Chemotherapy for Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Unfit for Cisplatin-Based Chemotherapy
by: Juan A. Marín-Jiménez, et al.
Published: (2022-07-01)

Cetuximab Plus Chemotherapy versus Chemotherapy Alone in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Cost-Effectiveness Analysis
by: Lang Y, et al.
Published: (2020-11-01)

Combination Antiemetic Therapy for Chemotherapy-Induced Nausea and Vomiting in Patients with NSCLC Receiving Carboplatin-Based Chemotherapy
by: Shimokawa M, et al.
Published: (2022-09-01)

THE DIFFERENCES OF APOPTOSIS EFFECTS BETWEEN COMBINATION OF MELOXICAM WITH GEMCITABINE-CARBOPLATIN CHEMOTHERAPY COMPARED TO GEMCITABINE-CARBOPLATIN CHEMOTHERAPY ALONE IN UROTHELIAL CARCINOMA CULTURE CELLS
by: Ananta Cahyo Nugroho, et al.
Published: (2019-01-01)

Patient‐reported symptom burden as a prognostic factor in treatment with first‐line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial
by: Akira Ooki, et al.
Published: (2020-03-01)

Evaluation of adjuvant chemotherapy in feline injection site-associated sarcoma
by: S.T. Pereira, et al.

Metastatic small‐cell carcinoma of the bladder that maintains a complete response to chemoradiation therapy
by: Shinya Miyazaki, et al.
Published: (2023-01-01)

Phase I Study of Ficlatuzumab and Cetuximab in Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Cancer
by: Julie E. Bauman, et al.
Published: (2020-06-01)

An Inflammatory Signature to Predict the Clinical Benefit of First-Line Cetuximab Plus Platinum-Based Chemotherapy in Recurrent/Metastatic Head and Neck Cancer
by: Stefano Cavalieri, et al.
Published: (2022-10-01)

Organizing pneumonia secondary to cetuximab in a patient with colorectal cancer
by: Abdulaziz AlGhulayqah, et al.
Published: (2019-09-01)

Successful Chemotherapy with Carboplatin and S-1 for Thymic Carcinoma: A Case Report
by: Satoshi Igawa, et al.
Published: (2013-10-01)

Observational study on quality of life, safety, and effectiveness of first‐line cetuximab plus chemotherapy in KRAS wild‐type metastatic colorectal cancer patients: the ObservEr Study
by: Carmine Pinto, et al.
Published: (2016-11-01)

Treatment of Rectal Cancer-Induced Disseminated Carcinomatosis of the Bone Marrow with FOLFOX plus Cetuximab and Panitumumab
by: Takehito Ehara, et al.
Published: (2020-02-01)

Lutetium 177-Labeled Cetuximab Evaluation for Radioimmunotherapeutic Applications
by: Kamal Yavari, et al.
Published: (2012-06-01)

Transgenic goats producing an improved version of cetuximab in milk
by: Götz Laible, et al.
Published: (2020-11-01)

A Case of Panitumumab-Responsive Metastatic Rectal Cancer Initially Refractory to Cetuximab
by: Yuta Kasagi, et al.
Published: (2013-07-01)